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Background: Postoperative pulmonary complications (PPCs) are associated with poor outcomes following
thoracotomy and lung resection. Video-assisted thoracoscopic surgery (VATS) for lobectomy is now frequently
utilised as an alternative to thoracotomy, however patients remain at risk for development of PPC. There is little
known of the short-term outcome associated with PPC following VATS lobectomy and if there are any potential risk
factors that could be modified to prevent PPC development; our study aimed to investigate this.
Methods: A prospective observational study of consecutive patients undergoing VATS lobectomy for lung cancer
over a 4-year period in a regional centre was performed (2012–2016). Exclusion criteria included re-do VATS or
surgery for pulmonary infection. All patients received physiotherapy as necessary from postoperative day 1 (POD1)
and PPC was determined using the Melbourne Group Scale. Outcomes included hospital LOS, intensive therapy
unit (ITU) admission and hospital mortality.
Results: Of the 285 patients included in the study, 137 were male (48.1%), the median (IQR) age was 69 (13) years
and the mean (±SD) FEV1% predicted was 87% (±19). Patients that developed a PPC (n = 21; 7.4%) had a
significantly longer hospital LOS (4 vs. 3 days), higher frequency of ITU admission (23.8% vs. 0.5%) and higher
hospital mortality (14.3% vs. 0%) (p < 0.001). PPC patients also required more physiotherapy contacts/time,
emergency call-outs and specific pulmonary therapy (p < 0.05). Current smoking and COPD diagnosis were
significantly associated with development of PPC on univariate analysis (p < 0.05), however only current smoking
was a significant independent risk factor on multivariate analysis (p = 0.015).
Conclusions: Patients undergoing VATS lobectomy remain at risk of developing a PPC, which is associated with an
increase in physiotherapy requirements and a worse short-term morbidity and mortality. Current smoking is the
only independent risk factor for PPC after VATS lobectomy, thus vigorous addressing of preoperative smoking
cessation is urgently needed.
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Lung cancer is the leading cause of cancer death in the
UK [1]. Lobectomy is widely considered the optimal ther-
apy for early stage non-small cell lung cancer (NSCLC)
[2]. Video-assisted thoracoscopic surgery (VATS) is
being increasingly performed for early-stage NSCLC
instead of open thoracotomy because of its minimally
invasive nature [3].
Postoperative pulmonary complications (PPCs) after
major thoracic surgery, such as pneumonia and clinically
significant atelectasis are common, and increase hospital
mortality, intensive therapy unit (ITU) admission and
hospital length of stay (LOS) [4]. Patients developing a
PPC also have a worse long-term outcome; after thoracot-
omy and lung resection PPC resulted in a 6-month reduc-
tion in the mean overall survival (p = 0.006) [5]. Risk
factors for developing PPC after thoracotomy and lung re-
section have been previously defined as age, smoking,
chronic obstructive pulmonary disease (COPD), percent-
age predicted forced expiratory volume in 1 s (FEV1) and
body mass index (BMI) [4–8].
The effect of VATS lobectomy in comparison to thora-
cotomy in reducing hospital LOS [9, 10] and postopera-
tive pain [11] is well established. It is also becoming
increasingly evident that a VATS approach may reduce
incidence of PPC [10, 12–14], however, developing a
PPC is still likely in patients undergoing VATS lobectomy,
and PPC frequency needs confirmation, as well as identify-
ing the effect of developing a PPC on short-term outcomes.
Furthermore, few studies have specifically addressed risk
factors associated with complications following VATS lob-
ectomy, which are mainly retrospective in design, have dif-
fering definition for PPC, and only investigate the less
frequent major complications [15–17].
The aims of this study were to investigate the effect of
PPC on short-term outcomes after VATS lobectomy and to
identify any risk factors associated with their development.
Methods
This prospective observational study was conducted be-
tween January 2012 and January 2016 at a large single
centre regional thoracic surgical unit serving six million
people. Consecutive patients undergoing (VATS) lobec-
tomy for cancer were included. Decision regarding patient
operability and resectability were informed by the British
Thoracic Society guidelines for lung cancer resection [18].
All patients were admitted to hospital on the day of sur-
gery, and operations performed with single lung ventila-
tion under general anaesthesia; patients were subsequently
scheduled for extubation in the operating room.
VATS was defined as per Swanson et al. [19]; involving
the use of a utility incision, without rib-spreading, two
further port incisions and use of a thoracoscope to visu-
alise the anatomical hilar dissection. Decisions regardingsurgical approach by VATS rather than thoracotomy were
initially conservative and based on guidance from national
and international centres with extensive experience. The
initial guidance included tumour size (< 7 cm), avoiding N1
involvement where known preoperatively on PET scan, no
neoadjuvant chemo/radio therapy, no visibility of the
tumour at bronchoscopy and no crossing of fissures by tu-
mours. Our VATS experience has since evolved, and our
cases have grown to include preoperatively identified N1 in-
volvement, previous neoadjuvant chemo/radio therapy, visi-
bility of the tumour at bronchoscopy requiring hand sewn
bronchial stump closure and tumours crossing fissures ne-
cessitating bi-lobectomy. Exclusion criteria included re-do
procedures (such as completion lobectomy) and where sur-
gery had been indicated for pulmonary infection.
Postoperatively patients were managed in a high-
dependency unit (HDU) (level 2) dedicated to thoracic
surgery, and/or the thoracic surgery ward, unless the
presence of complications required admission to the
ITU (level 3) such as the need for invasive ventilation.
The choice of analgesic technique was made by the an-
aesthetist after discussion with the patient. Postoperative
pain control was achieved either by continuous thoracic
epidural analgesia, paravertebral infusion, intrathecal
morphine and/or intercostal blocks or systemic opioids
(intravenous patient-controlled administration or paren-
teral administration).
Postoperative care also included nursing staff sitting
patients out of bed on postoperative day 1 (POD1); at
this point patients also started early mobilisation as able,
with assistance as necessary for surgical attachments and
safety. All patients were assessed by specialist thoracic sur-
gery physiotherapists on POD1 in order to determine pres-
ence of issues amenable to physiotherapy intervention,
such as atelectasis, sputum retention, or reduced mobility/
exercise tolerance. Physiotherapy treatment was then com-
menced as necessary in the relevant patients to clear secre-
tions, improve lung volume or for specific mobility issues;
to both increase reduced physical activity level beyond that
achieved with standard care, and to regain independence. If
physiotherapy was not deemed necessary patients contin-
ued with standard postoperative care. Where pulmonary
complication developed physiotherapy input was escalated
as appropriate. All patients received physiotherapy until
resolution of pulmonary issues, and/or usual mobility inde-
pendence and exercise tolerance were restored.
Data collected included demographics and preoperative
record of BMI, % predicted FEV1, American Society of
Anesthetist (ASA) score, smoking status, subjective pre-
operative activity level and COPD diagnosis defined by the
referring clinician. Smoking data was collected by patients
self-reporting to the specialist thoracic research team (in-
cluding nurses and physicians) at the pre-operative assess-
ment, and on hospital admission using a paper based case
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electronic database. Current smokers were defined as
those who continued smoking up to the date of surgery.
Postoperative data collection included pathology reports
of either primary NSCLC (staging using TNM 7th edition)
or secondary metastatic disease. Hospital LOS was defined
as the LOS in hospital after the date of surgery. HDU LOS
and ITU admission and in-hospital mortality were also re-
corded. PPC was identified using a standardised scoring
system named the Melbourne Group Scale (MGS), which
has been previously validated by our group to define
the presence of PPCs, such as pneumonia or clinically
significant atelectasis [4, 20]. PPC is defined in those
patients presenting with four or more of the following
eight dichotomous factors: chest X-ray (CXR) findings
of atelectasis or consolidation; raised white cell count
(WCC) (> 11.2 × 109/L); temperature > 38 °C; signs of
infection on sputum microbiology; purulent sputum
differing from preoperative status; oxygen saturations
(SpO2) < 90% on room air; physician diagnosis of
pneumonia; and prolonged HDU stay or readmission to
HDU or ITU for respiratory complications. The MGS
variables were assessed from POD1 daily by specialist
physiotherapists during assessment and treatment sessions.
This study was conducted with the approval of the
National Research Ethics Service (NRES) Committee
West Midlands. This study was registered with the
Birmingham Heartlands Hospital audit department (audit
code 1672).Statistical analysis
Normally distributed continuous variables are expressed
as mean (±SD), skewed continuous variables as median
(interquartile range), and categorical variables as actual
number (percentages). Normality of distributions was
assessed using the Kolmogorov-Smirnov test. Differences
in baseline characteristics and postoperative outcomes
were analysed using Chi-square tests for categorical vari-
ables, Fisher’s exact test for categorical variables where
numbers per cell were 5 or less, Independent samples
t-test for continuous variables and Mann-Whitney U
tests for continuous variables with skewed distributions;
p-values < 0.05 were considered significant.
In order to determine if any factors were associated
with the development of PPC tests of difference as above
were performed to determine which preoperative base-
line characteristics were significantly associated with
PPC on univariate analysis. Any significant variables
were entered into a forward stepwise logistic regression
analysis to determine those independently associated
with development of PPC, and to estimate the odds ratio
(OR) and their 95% confidence interval (CI). Analysis
was performed using IBM Statistics SPSS Version 22.Results
Study population
Over the 4-year period, 291 patients underwent lobec-
tomy using a VATS approach. Six cases were excluded; 4
were procedures undertaken for treatment of chronic
lung infections and 2 were revisions or completion lob-
ectomy. Of the 285 patients included in the study, the
baseline demographics are shown in Table 1.
Postoperative pulmonary complications
Twenty-one (7.4%) patients developed a PPC, most fre-
quently (median) on POD3 (Fig. 1). Three patients devel-
oped a ‘late’ PPC, over a week after surgery (PODs 8, 9
and 13). The cases on POD8 and 9 could not be attributed
as secondary to any other complication, whilst the case on
POD13 was most likely related to a cerebro-vascular acci-
dent (CVA) immediately following surgery, and ensuing
mechanical ventilation. The most common variables scor-
ing positive in cases of PPC were CXR findings, elevated
WCC and SpO2 < 90% on room air (Fig. 2).
Outcomes
In those with PPC there was a significantly higher LOS,
ITU admission and hospital mortality (p < 0.001) (Table 2).
Of the 6 patients admitted to ITU, all developed a PPC
apart from 1 patient who was admitted there following fail-
ure to wake after anaesthesia. Of the 5 patients who devel-
oped a PPC, 3 were admitted to ITU specifically because of
the PPC, the other 2 developed PPC subsequent to the
ITU admission. The only deaths in the study were in 3 of
the 6 patients admitted to the ITU; 2 patients died second-
ary to a PPC, and 1 patient died secondary to a CVA.
Early mobilisation
Postoperative early mobilisation is shown in Table 3.
Most patients (n = 275, 96.5%) were able to sit out of
bed on POD1. In total 42 patients (14.7%) were unable
to mobilise on POD 1; 10 (3.5%) were unable to sit out
of bed at all and 32 (11.3%) were unable to mobilise
further to their transfer out of bed. There was a signifi-
cant association between reduced early mobilisation on
POD1 and patients who went on to develop PPC (n = 7).
Reasons patients were unable to mobilise on POD1 are
included in Fig. 3.
Physiotherapy
Two hundred nine (73.6%) patients received physiother-
apy treatment, with a median of 4 physiotherapy sessions
in total. All 209 patients’ data showed that their physio-
therapy treatment included mobilisation or exercise re-
gardless of whether they primarily had a mobility issue or
a pulmonary problem. 23 (8.1%) patients additionally re-
quired therapy to aid sputum clearance and deep breath-
ing exercises were taught to 65 (22.8%) specifically for
Table 1 Baseline characteristics of PPC and non-PPC patients
Total
(n = 285)
PPC
(n = 21)
Non-PPC
(n = 264)
p value
Gender (male) 137 (48.1%) 13 (61.9%) 124 (47%) 0.28
Age (years) median, IQR 69.0 (13) 70.0 (10) 69.0 (13) 0.84
FEV1% predicted mean (±SD) 87.0 (±19) 88.8 (±21.6) 87.5 (±19.8) 0.78
ASA score≥ 3 144 (50.5%) 14 (66.7%) 130 (49.2%) 0.19
Preoperative activity level≤ 400 m 84 (29.5%) 7 (8.4%) 77 (91.6%) 0.88
BMI ≥30 63 (22.1%) 4 (19%) 59 (22.3%) 0.49
COPD 84 (29.5%) 11 (52.4%) 73 (27.7%) 0.03
Current smoker 60 (21.1%) 9 (42.9%) 51 (19.3%) 0.02
NSCLC Staging IA 118 (45.7%) 9 (52.9%) 109 (45.2%) 0.54
IB 83 (32.2%) 4 (23.5%) 79 (32.8%)
IIA 40 (15.5%) 2 (11.8%) 38 (15.8%)
IIB 5 (1.9%) 0 (0%) 5 (2.1%)
IIIA 12 (4.7%) 2 (11.8%) 10 (4.1%)
Secondary metastatic disease 27 (9.5%) 4 (14.8%) 23 (85.2%) 0.12
Analgesia Paravertebral 233 (81.8%) 18 (85.7%) 215 (81.4%) 0.19
Epidural 27 (9.5%) 0 (0%) 27 (10.2%)
PCA / othera 25 (8.8%) 3 (14.3%) 22 (8.3%)
PPC, postoperative pulmonary complication; ASA, American Society of Anaethesiologists; BMI, body mass index; COPD, chronic obstructive pulmonary disease; PCA,
patient controlled analgesia; amorphine infusion (n = 3)
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was required by patients who developed a PPC; they had
significantly more therapist contacts and time spent on
treatment (Table 4). These patients had more specific pul-
monary therapies and out of hours therapy.
Risk factors
Univariate analysis revealed significantly higher frequency
of COPD and current smokers in those with PPC (p < 0.05)
(Table 1). Forward stepwise logistic regression was per-
formed to determine factors independently associated with
development of a PPC following VATS lobectomy. Only
current smoking and COPD diagnosis were signifi-
cantly more frequent in patients who had developedFig. 1 Day PPC detected following surgeryPPC following univariate analysis (p < 0.05) and were there-
fore included in the model. A significant contribution to the
model was only made by current smoking; the OR com-
pared to non-smokers was 3.1 (95% CI 1.3–7.8; p < 0.015).
Discussion
Our study has shown a PPC frequency of 7% in cancer pa-
tients undergoing VATS lobectomy. Though this is rela-
tively less common when compared to patients undergoing
a thoracotomy approach [5, 12], we have demonstrated that
PPC following VATS lobectomy is still associated with sig-
nificantly worse short-term outcomes including increased
ITU admission, increased hospital LOS and a higher hos-
pital mortality. Furthermore, patients undergoing VATS
Fig. 2 Frequency of PPC positive variables in patients who developed PPC
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including sputum clearance and lung expansion therapy.
Current smoking was the only significant independent
factor associated with developing a PPC after VATS
lobectomy.
Other studies have reported the incidence of PPC after
VATS to vary between 10 to 40% [16, 17, 21], which is
likely due to a lack of a standardised definition used. We
have used the MGS to detect PPC such as pneumonia
and clinically significant atelectasis [22], these complica-
tions have been described after VATS with an incidence of
3 to 7.5% [13, 14, 23] and 3 to 13.6% respectively [16, 21].
The MGS was initially utilised in patients undergoing
thoracotomy and does not include such rare and serious
postoperative complications such as broncho-pleural fis-
tulas and pulmonary embolism. However, our study has
validated its use in VATS lobectomy, and has shown that
the more frequent and probably less severe PPCs detected
by the MGS in these individuals are still associated with a
significantly higher short-term morbidity and mortality.
The majority of patients were found to have issues po-
tentially amenable to physiotherapy, which were mainly
mobility issues; only around a quarter received physio-
therapy to ameliorate specific pulmonary problems, such
as atelectasis or increased/retained secretions. Addition-
ally, patients who developed a PPC as recognised by the
MGS required significantly more physiotherapy input inTable 2 Hospital morbidity and mortality in PPC compared to non-P
Outcomes PPC
(n = 21)
Hospital LOS (days) median (IQR) 4 (3)
ITU Admission (%) 5 (23.8%)
a3 (14%)
Hospital mortality (%) 3 (14.3%)
a2 (9.5%)
PPC, postoperative pulmonary complication; ITU, intensive treatment unit; LOS, leng
PPC relatedthe postoperative period (up to three times that of other
patients requiring therapy). The amount of patients re-
quiring physiotherapy is less following VATS than thora-
cotomy [12], but with the frequency of mobility issues,
pulmonary problems and PPC observed in this study we
would recommend ‘routine’ physiotherapy assessment
following VATS lobectomy, so that issues amenable to
physiotherapy can be identified early.
We sought to find independent risk factors that were
significantly associated with PPC following VATS. Previ-
ous studies have investigated the risk factors for PPC de-
velopment after thoracotomy [4–8], but few have
addressed this in VATS [15–17]. Yang et al. [17] retro-
spectively reported major complications that occurred in
7.3% of VATS cases for primary lung cancer, of which
pulmonary complications represented 90.7% of these.
The risk factors identified for major complications in-
cluded age > 70 years, prolonged operation time and co-
morbidities including cerebrovascular disease, COPD,
chronic renal insufficiency or diabetes mellitus. Interest-
ingly, smoking was only defined as pack years (≥20) and
although significant on univariate analysis (p = 0.002)
was not significant on multivariate analysis. Wang et al.
[16] studied patients (n = 525) who underwent VATS for
lung cancer. Only the major complications occurring in
6.9% of patients were studied which including respira-
tory failure, haemothorax, myocardial infarction, heartPC group
Non-PPC
(n = 264)
p value
3 (2) < 0.001
1 (0.5%) < 0.001
0.005
0 (0%) < 0.001
0.003
th of stay; anumber of first mortality/ITU admission figure that were
Table 3 Early mobilisation of all patients on POD1
Early Mobility on POD1 Total
(n = 285)
PPC
(n = 21)
Non-PPC
(n = 264)
p value
Unable to mobilise 42 (14.7%) 7 (33.3%) 35 (13.3%) 0.05
Distance Walked < 10 m 6 (2.1%) 0 (0%) 6 (2.3%)
Distance Walked > 10 m 237 (83.2%) 14 (66.7%) 223 (84.5%)
Unable to Sit Outa 10 (3.5%) 2 (9.5%) 8 (3%) 0.16
POD1, postoperative day 1. aThese patients are included in the group who
were unable to mobilise
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monary embolism. The significant independent risk fac-
tors for these major complications were age > 70 years,
FEV1 < 70% predicted and cardiovascular disease. How-
ever, this study is limited by its retrospective nature and
the extremely high proportion of never smokers (58.5%)
and patients without COPD (93.5%). Our finding that
FEV1% predicted was not predictive of PPC in VATS are
support by Berry et al. [15], who found that in VATS lob-
ectomy cases (n = 173) FEV1 was not significant inde-
pendent risk factors for the 12% of patients who
developed a PPC. In our study carbon monoxide lung dif-
fusion capacity (DLCO) was performed only in patients
with reduced exercise tolerance or lung volumes so data
are limited, however DLCO was also found not to be a
risk factor for PPC in VATS lobectomy patients [15].
To investigate the risk factors for developing PPC in
patients undergoing VATS lobectomy the specific vari-
ables used in this study (age, ASA score, BMI, COPD,
smoking status) were chosen as possible confounders as
they had previously been shown to be independent associ-
ated with PPC following thoracotomy and lung resection in
our patient group [4]. Other comorbidities such as ischae-
mic heart disease, heart failure, hypertension and diabetesFig. 3 Reasons for not mobilising in POD1were not previously identified as an increased risk for PPC,
and therefore were not investigated in this study [5].
Our study found that smoking was the only risk factor
for PPC after VATS lobectomy, which is supported by
previous studies finding smoking to be the major risk
factor for PPC after thoracic surgery for lung resection
[4, 5]. We found that 1 in 5 patients continued to smoke
up until the date of VATS lobectomy for lung cancer,
and despite having being minimally invasive surgery,
these patients were still 3 times more likely to develop a
PPC than non-smokers. The observed effects of smoking
on the increased incidence of PPC could be explained by
the suppressive effect of cigarette smoking on the innate
immune system. An earlier study suggested an increased
risk of PPC in patients who stop smoking within 4 weeks
of thoracotomy and lung resection [24], though this
study was limited by its retrospective design and has
since been superseded. More recent evidence has shown
that the risk of PPC after thoracotomy reduces with
smoking cessation, but no optimal time can be defined
[25, 26]. Currently in the UK there is no integrated pre-
operative smoking cessation service in thoracic surgery,
as only community based cessation services exist. How-
ever, these community services are designed to promote
long-term quitting, which many smokers due to undergo
lung cancer surgery may not be willing to commit to
and most report difficulty in attending given their imme-
diate clinical appointments; patient preference therefore
is for an integrated approach [27]. We are planning to
undertake a feasibility study to investigate if personalised
intense smoking cessation intervention integrated into
the thoracic surgical pathway improves smoking cessa-
tion rates when compared to usual care of standard
community based NHS smoking cessation.
Table 4 Physiotherapy in PPC compared to non-PPC group
Physiotherapy PPC
(n = 21)
Non-PPC
(n = 264)
p value
Need for Physiotherapy 21 (100%) 128 (48.9%) 0.002
On-call Physiotherapy (out of hours) 7 (33.3%) 4 (1.5%) < 0.001
Number of contacts median (IQR) 10 (12) 3 (3) < 0.001
Therapy time in minutes median (IQR) 220 (283) 70 (59) < 0.001
Specific pulmonary interventions 16 (76.2%) 58 (22%) < 0.001
POD1, postoperative day 1
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This is the first prospective observational study to inves-
tigate the risk factors associated with the development
of PPC in patients undergoing VATS lobectomy. One
limitation of this study is that smoking status was self-
reported by patients prior to surgery, and although pa-
tients tend to under-report smoking status, biochemical
confirmation would need to confirm this in future stud-
ies. Another limitation of the study is that the protocol
of postoperative analgesia was not the same in all pa-
tients. For example, none of the patients who developed
a PPC had an epidural catheter. Despite this, we have
previously demonstrated in a large group of thoracic sur-
gery patients that choice of analgesia was not a risk fac-
tor for the development of PPC after lung resection [5].
Finally, we recognise a limitation to the findings of the
study with the small number of patients who developed
PPC within the regression model; in a larger cohort it is
possible that other risk factors may have been identified.
However, the lower frequency of PPC following VATS
lobectomy precludes the observation of a large group in
a timely manner.Conclusions
Despite the minimally invasive nature of surgery patients
undergoing VATS lobectomy for cancer remain at risk of
developing a PPC, which is associated with significantly
worse short-term morbidity and mortality. Physiotherapy
was applied in most patients to ameliorate mobility or pul-
monary issues, however, those developing a recognised
PPC required significantly more treatment. Current smok-
ing is an independent risk factor for PPC following VATS
lobectomy, thus vigorous addressing of preoperative smok-
ing cessation is urgently needed.Abbreviations
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